Rheonix Receives Additional $233K Award from National Institutes of Health

Ithaca, N.Y. — August 17, 2010 — Rheonix, Inc. today announced that the National Institutes of Health has added a $233,044 supplement to its previously awarded Point-of-Care Partnership grant. The POC Partnership grant is funded to develop a fully automated molecular diagnostic for the detection of multiple sexually transmitted infections (STI). The supplement, awarded under the American Recovery and Reinvestment Act (ARRA) of 2009, was added to expand the scope of efforts to also include the molecular detection of urinary tract infections (UTI).

Tony Eisenhut, Rheonix President, commented, “this competitive awarding of the ARRA supplement further validates our scientific approach as we continue to make excellent progress toward completing a fully automated CARD™ device for the rapid molecular detection of multiple sexually transmitted diseases. Since the original grant was focused on point-of-care testing in nontraditional settings, NIH has recognized the diagnostic value of being able to simply introduce a raw sample and perform all sample preparation, analysis and readout without any user intervention.”

Richard Montagna, Ph.D., Senior Vice President for Scientific Affairs and the project’s Principal Investigator added, “our proprietary low cost production methods will also permit the introduction of these POC devices at very competitive prices, thereby helping to reduce the growing cost of health care.”

Rheonix receives FDA Emergency Use Authorization for Automated COVID-19 Test.
Learn More